Plain-English translation of NCT06965114 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a newer cancer drug, works well when combined with (an existing treatment) for hairy cell leukemia. Researchers want to see if this combination is safe and if it can help patients achieve long-term remission. The study has two parts: one testing the medication in patients whose disease has come back or stopped responding to prior treatment, and another comparing this new combination to the current standard treatment for newly diagnosed patients.
Hairy cell leukemia is a rare blood cancer, and while current treatments work for many patients, some people's cancer comes back or doesn't respond well. Researchers hope this new medication will offer another effective option with potentially fewer side effects or better long-term results.
You likely qualify if…
You likely don't qualify if…
Participants will take the medication by mouth once a week (or on specific days of each cycle) and receive through an IV infusion on certain weeks or days over roughly 4 months. You'll have frequent blood tests, CT scans as needed, and bone marrow biopsies to check how well the treatment is working. Regular visits to the clinic will be needed to monitor your health, watch for side effects, and adjust treatment if necessary.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States